Leishmania antigens suitable for a diagnostic kit of Leishmania

• US 20060211056A1
• Filed: 01/24/2006
• Published: 09/21/2006
• Est. Priority Date: 01/25/2005
• Status: Abandoned Application

• Current Assignee: Institut Pasteur
• Original Assignee: Institut Pasteur
• Inventors: Dellagi, Koussay, Guizani, Ikram, Kamoun-Essghaier, Sayda
• Application Number:
  US11/337,801
• Publication Number:
  US 20060211056A1
• Time in Patent Office: Days
• US Class Current: 435/7.220
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/44 from protozoa
• CPC Class Codes: C07K 16/20 from protozoa
• CPC Class Codes: G01N 2333/44 from protozoa
• CPC Class Codes: G01N 33/56905 Protozoa
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A purified Leishmania infantum polypeptide comprising at least 10 consecutive amino acids of a protein is provided. The protein is mitochondrial integral ADP/ATP carrier protein, NADH-cytochrome b5 reductase, mitochondrial carrier protein, guanine nucleotide binding protein beta subunit (LACK), aldehyde reductase, ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4 kDa, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5 kDa, or truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa. Methods for using the polypeptides for diagnosing MVL are disclosed.

Claims

1. A purified Leishmania infantum polypeptide comprising at least 10 consecutive amino acids of a protein, wherein said protein is mitochondrial integral ADP/ATP carrier protein, NADH-cytochrome b5 reductase, mitochondrial carrier protein, guanine nucleotide binding protein beta subunit (LACK), aldehyde reductase, ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4 kDa, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5 kDa, or truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa.

2. The polypeptide of claim 1, wherein said polypeptide comprises at least 20 consecutive amino acids of said protein.

3. The polypeptide of claim 2, wherein said polypeptide comprises at least 30 consecutive amino acids of said protein.

4. The polypeptide of claim 1, wherein said polypeptide comprises a Leishmania immunodominant antigen.

5. The polypeptide of claim 1, wherein said polypeptide is recombinant.

6. A purified antibody that binds to at least one polypeptide of claim 1.

7. The purified antibody of claim 6, wherein the antibody is a monoclonal antibody.

8. A method for diagnosing Mediterranean visceral leishmaniasis (MVL), wherein the method comprises providing a composition comprising biological material suspected of being infected with Leishmania infantum, and assaying for the presence of antigens in the biological material that are immunologically reactive with an antibody of claim 6.

9. The polypeptide of claim 1, wherein said protein is mitochondrial integral ADP/ATP carrier protein.

10. The polypeptide of claim 1, wherein said protein is NADH-cytochrome b5 reductase.

11. The polypeptide of claim 1, wherein said protein is mitochondrial carrier protein.

12. The polypeptide of claim 1, wherein said protein is guanine nucleotide binding protein beta subunit (LACK).

13. The polypeptide of claim 1, wherein said protein is aldehyde reductase.

14. The polypeptide of claim 1, wherein said protein is ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein.

15. The polypeptide of claim 1, wherein said protein is truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4.

16. The polypeptide of claim 1, wherein said protein is truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5.

17. The polypeptide of claim 1, wherein said protein is truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa.

18. A diagnostic kit for detecting the presence or absence of antibodies which bind to Leishmania comprising at least one polypeptide of claim 1, and means for detecting the formation of an immune complex between said polypeptide and antibodies, wherein said means are present in an amount sufficient to perform said detection.

19. The kit of claim 18, wherein said means for detecting the formation of immune complex between the polypeptide and antibodies comprises an indirect immunofluorescence assay, a direct agglutination test, or an enzyme-linked immunosorbent assay (ELISA).

20. An immunogenic composition comprising at least one polypeptide of claim 1 in an amount sufficient to induce an immunogenic or protective response in vivo, and a pharmaceutically acceptable carrier therefor.

21. The immunogenic composition of claim 20, wherein said composition comprises a neutralizing amount of said polypeptide.

22. An immunological complex comprising a polypeptide of claim 1, and an antibody that specifically recognizes said polypeptide.

23. A method for diagnosing Mediterranean visceral leishmaniasis (MVL), wherein the method comprises providing a composition comprising biological material suspected of being infected with Leishmania infantum, and assaying for the presence of antibodies in the biological material that are immunologically reactive with a polypeptide of claim 1.

24. An in vitro diagnostic method for the detection of the presence or absence of antibodies, which bind to a polypeptide of claim 1, wherein the method comprises contacting the polypeptide with a biological fluid for a time and under conditions sufficient for the polypeptide and antibodies in the biological fluid to form an antigen-antibody complex, and detecting the formation of the complex.

25. The method of claim 24, which further comprises measuring the formation of the antigen-antibody complex.

26. The method of claim 24, wherein the formation of antigen-antibody complex is detected by immunoassay based on Western blot technique, ELISA, indirect immunofluoresence assay, or immunoprecipitation assay.

27. A mixture of purified Leishmania infantum polypeptides comprising at least two of mitochondrial integral ADP/ATP carrier protein, NADH-cytochrome b5 reductase, mitochondrial carrier protein, guanine nucleotide binding protein beta subunit (LACK), aldehyde reductase, ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4 kDa, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5 kDa, or truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa,

wherein said mixture is essentially free of lipids.

28. The mixture of claim 27, wherein each of said polypeptides has a molecular weight of approximately 30-36 kDa as determined by SDS-PAGE.

29. The mixture of claim 27, wherein said polypeptides comprise Leishmania immunodominant antigens.

30. The mixture of claim 27, wherein said polypeptides are recombinant polypeptides.

31. A diagnostic kit for Mediterranean visceral leishmaniasis (MVL), wherein said kit comprises the mixture of claim 27, and means for detecting the formation of immune complex between antigen and antibodies, wherein the means are present in an amount sufficient to perform said detection.

32. The kit of claim 31, wherein said means for detecting the formation of immune complex between the antigen and antibodies comprises an indirect immunofluorescence assay, a direct agglutination test, or an enzyme-linked immunosorbent assay (ELISA).

33. A method for identifying a polypepitde from Leishmania promastigotes comprising the steps of:

a) providing Leishmania membrane antigens;

b) electrophoresing said membrane antigens;

c) transferring said membrane antigens to a suitable surface;

e) contacting said membrane antigens with Mediterranean visceral leishmaniasis (MVL) sera and Zoonotic cutaneous leishmaniasis (ZVL) sera under conditions sufficient to form antigen-antibody complexes;

f) detecting the formation of said antigen-antibody complexes; and

g) identifying a polypeptide that reacts with MVL sera but not ZCL sera.

34. The method of claim 33, wherein said identifying a polypeptide that reacts with MVL sera but not ZCL sera comprises amino acid sequencing.

35. The method of claim 33, wherein said identifying a polypeptide that reacts with MVL sera but not ZCL sera comprises liquid chromatography mass spectrometry.

36. The method of claim 33, wherein said polypeptide forms a complex with antibodies in the biological fluid from Mediterranean visceral leishmaniasis patients, and wherein said polypeptide does not form a complex with antibodies in the biological fluid from patients infected with Trypanosoma cruzi, Mycobacteria, malaria parasites, or amoeba.

37. The method of claim 33, wherein said method further comprises detecting a polypeptide-antibody complex by immunoassay based on Western blot technique, ELISA, indirect immunofluorescence assay, or immunoprecipitation assay.

38. The method of claim 33, wherein said electrophoresis comprises two dimensional non equilibrium pH gradient electrophoresis.

39. A purified nucleic acid encoding a polypeptide comprising at least 10 consecutive amino acids of a protein, wherein said protein is mitochondrial integral ADP/ATP carrier protein, NADH-cytochrome b5 reductase, mitochondrial carrier protein, guanine nucleotide binding protein beta subunit (LACK), aldehyde reductase, ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4 kDa, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5 kDa, or truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa.

40. A purified nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of claim 39 under conditions of moderate stringency in 50% formamide and 6×

SSC at 42°

C., with washing conditions of 0.5×

SSC and 0.1% SDS at 60°

C.

41. A purified nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of claim 39 under conditions of high stringency in 50% formamide and 6×

SSC at 42°

C., with washing conditions of 0.2×

SSC and 0.1% SDS at 68°

C.

43. A recombinant vector that directs the expression of a nucleic acid molecule selected from the group consisting of the purified nucleic acid molecules of any one of claims 39, 40, 41, and 42.

42. A purified nucleic acid molecule, which encodes mitochondrial integral ADP/ATP carrier protein, NADH-cytochrome b5 reductase, mitochondrial carrier protein, guanine nucleotide binding protein beta subunit (LACK), aldehyde reductase, ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4 kDa, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5 kDa, or truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa.